How to Treat SVT: Stopping Episodes and Long-Term Fixes

SVT episodes can often be stopped at home with simple physical techniques, and when those fail, fast-acting drugs given in an emergency department will terminate most episodes within seconds. For people who get SVT repeatedly, catheter ablation is the treatment most likely to eliminate the problem for good, with long-term success rates above 90 percent for common types. The path from a first racing-heart episode to a permanent fix involves a few distinct layers of treatment, each suited to different moments and different levels of severity.

Stopping an Episode Right Now

The first thing to try during an SVT episode, if you’re conscious, alert, and not feeling faint or short of breath, is a vagal maneuver. These are physical techniques that stimulate the vagus nerve, which slows electrical conduction through the heart and can snap it out of the abnormal rhythm. The most familiar one is the Valsalva maneuver: you bear down hard as if straining on the toilet, holding that effort for about 15 seconds. Another option is dunking your face in ice-cold water or pressing a bag of ice against your face to trigger the “diving reflex,” which has a similar slowing effect on the heart.

If you’ve been told to try the Valsalva, there’s a detail worth knowing. The standard version, where you simply strain and then release, converts SVT to normal rhythm only about 10 to 25 percent of the time. A modified version, where you strain for 15 seconds and then immediately lie flat with your legs raised by someone else for another 15 seconds, roughly doubles the success rate. One randomized trial found the modified technique restored normal rhythm in about 43 percent of patients versus roughly 11 percent with the standard approach.¹ A meta-analysis pooling several trials confirmed the modified version was significantly more effective both on the first attempt and overall.² Another trial comparing multiple vagal techniques found that the modified Valsalva also held up better at the five-minute mark, with about 28 percent of patients still in normal rhythm compared to only 6 percent from the standard Valsalva and 3 percent from carotid sinus massage.³

The practical takeaway: if you feel an episode starting, try bearing down hard for 15 seconds and then quickly lie flat and have someone lift your legs. It costs nothing, carries no risk, and works often enough to be worth doing before heading to the emergency department.

What Happens in the Emergency Department

When vagal maneuvers don’t work or the episode is too uncomfortable to ride out, the next step is adenosine. This drug is given as a rapid push through an IV, and it temporarily blocks electrical conduction through the AV node, essentially hitting a reset button on the heart’s rhythm. The effect is dramatic and almost instant: most people feel a brief chest tightness or a strange “sinking” sensation for a few seconds before the heart snaps back to its normal pace. The side effects are real but fleeting, typically fading within 30 seconds.

Dosing matters. A study comparing higher-dose and lower-dose adenosine found that the higher dose converted SVT on the first try in about 93 percent of cases, versus roughly 60 percent for the lower dose, with no meaningful difference in side effects between the two groups.⁴ If the first dose doesn’t work, a second, larger dose is typically given.

Verapamil, a calcium channel blocker, is the main alternative. It works more slowly than adenosine but keeps the heart in normal rhythm for longer once it does work. A systematic review comparing the two found that adenosine acts faster and is safer when the diagnosis is uncertain or the patient has low blood pressure or reduced heart function, while verapamil may be preferred when neither of those concerns applies.⁵ Verapamil should not be used in someone already taking a beta blocker, because combining them can dangerously slow the heart.

For the rare patient whose SVT causes dangerously low blood pressure, confusion, or chest pain suggesting the heart is struggling, synchronized cardioversion (a controlled electrical shock delivered under sedation) is first-line treatment. This applies to a small minority of SVT cases, but it works immediately and is lifesaving when needed.⁶

Living with Recurrent SVT on Medication

If SVT episodes come back frequently and you’re not ready for (or don’t have access to) an ablation, daily medication can reduce how often episodes happen and how fast the heart goes when they do. Beta blockers and calcium channel blockers are the usual choices. They don’t cure SVT; they slow conduction through the AV node enough to make episodes less likely or easier to tolerate.

Some people are offered a “pill-in-the-pocket” approach instead of daily medication. The idea is that you carry a dose of a beta blocker or calcium channel blocker and take it only when an episode starts, rather than every day. It sounds appealing, but the evidence behind it is thin. The onset of action is slow compared to how fast SVT symptoms escalate, and the strategy carries its own side-effect risks. A recent review noted that this approach is not well supported by clinical guidelines or robust trial data.⁷ It may work for occasional, mild episodes, but it’s not a reliable strategy for someone whose SVT causes significant symptoms.

Medication also comes with quality-of-life costs that are easy to underestimate. In one study comparing patients on long-term drugs to those who had an ablation, both groups saw improvement in symptoms, but the ablation group did better on measures of general health, energy, bodily pain, and emotional wellbeing. About three-quarters of ablation patients reported complete freedom from SVT symptoms, compared to only a third of those managed with medication.⁸ Another study found that medication alone was associated with more adverse events and more emergency department visits.⁹

Catheter Ablation as a Permanent Fix

For most people with recurrent SVT, catheter ablation is the definitive treatment. A thin, flexible catheter is threaded through a vein in the groin up to the heart, where it delivers energy to destroy the tiny patch of tissue responsible for the abnormal electrical circuit. The procedure usually takes one to three hours, requires only mild sedation or light general anesthesia, and most people go home the same day or the next morning. Guidelines now recommend ablation as first-line long-term management for recurrent, symptomatic SVT, including in patients with Wolff-Parkinson-White syndrome.⁶

Two types of energy are commonly used. Radiofrequency (RF) ablation uses heat to create a small scar, while cryoablation uses extreme cold. Both are effective, and a large long-term study found them equally so for the most common type of SVT (called AVNRT).¹⁰ However, a more recent study with very long follow-up suggests the recurrence rate may be higher with cryoablation. Over about three years, documented recurrence occurred in roughly 9 percent of cryoablation patients versus about 3 percent of radiofrequency patients, a statistically significant difference.¹¹ One advantage of cryoablation is that the freezing can be tested before committing: if the catheter is in a spot that might damage normal conduction, the effect can be reversed by warming the tissue. Radiofrequency damage, once done, is permanent.

In children, the numbers are encouraging. A study tracking outcomes after ablation for AVNRT in pediatric patients found freedom from recurrence of about 96 percent at one year, 93 percent at five years, and 89 percent at eight years, with no difference based on the type of energy used, age, sex, or body weight.¹²

Risks of Ablation and Who Should Think Twice

Catheter ablation is considered low-risk, but it is not risk-free. The most significant concern is damage to the heart’s normal electrical wiring (the AV node), which would require a permanent pacemaker. For AVNRT ablation, the risk of needing a pacemaker right around the time of the procedure is about 0.5 percent.¹³ Pulmonary embolism occurs in up to about 0.2 percent of cases.¹⁴

There’s a subtler risk that often goes unmentioned. A nationwide cohort study following over 6,800 AVNRT ablation patients for a median of about five and a half years found that 1.4 percent eventually needed a pacemaker more than 30 days after the procedure, compared to 0.4 percent of matched controls who never had an ablation.¹³ That means the ablation itself may cause some slow, late damage to the conduction system in a small number of patients. The absolute risk is still low, but it’s worth knowing about, especially for younger patients who will live with their ablation scar for decades.

The risk calculus also depends on the type of SVT. When an accessory pathway sits very close to the heart’s normal wiring (as can happen in some Wolff-Parkinson-White cases), ablation carries a higher chance of AV block.¹⁴ Cryoablation is sometimes chosen in these situations precisely because its effects can be tested and reversed before permanent damage occurs.

Healthcare Use After Ablation Versus Staying on Medication

One argument for ablation that doesn’t always come up in the initial conversation with your doctor is what happens to your healthcare costs and burden afterward. A propensity-matched study comparing ablation patients to medication-only patients found that by the second and third years after the procedure, overall healthcare use and spending in the ablation group dropped to levels comparable to the medication group. Fewer ablation patients still needed prescriptions for heart-rhythm drugs: about 32 percent, compared to 42 percent in the medication group.¹⁵ So while ablation has a higher upfront cost, it can reduce or eliminate the ongoing burden of daily medication, regular cardiology visits, and emergency department trips for breakthrough episodes.

SVT During Pregnancy

Pregnancy is one of the most common triggers for a first SVT episode or a worsening of an existing rhythm problem, thanks to the increased blood volume, faster resting heart rate, and hormonal shifts that come with carrying a baby. Treatment during pregnancy is complicated by the fact that all antiarrhythmic drugs cross the placenta. The general approach is to avoid any medication during the first trimester when the risk of birth defects is highest, and to use the lowest effective dose of the safest available drug when treatment becomes necessary later on.¹⁶

Intravenous adenosine is considered safe in all three trimesters and during labor, making it the go-to drug for terminating acute episodes in pregnant women. Beta blockers like atenolol and calcium channel blockers like verapamil can be used for ongoing control during the second and third trimesters but are generally avoided in the first.¹⁷ Electrical cardioversion is safe at any stage of pregnancy but carries a small risk of triggering preterm labor in the third trimester.¹⁷ A 2023 expert consensus statement emphasizes that the guiding principle is to use drugs with the longest track record of safety, at the lowest dose that works, with regular reassessment of whether the medication is still needed.¹⁸

For pregnant patients whose SVT is truly refractory to everything else, non-fluoroscopic catheter ablation (using mapping systems that don’t require X-ray exposure) has been performed successfully and is the only treatment that definitively eliminates the arrhythmia without recurrence.¹⁷ It remains a last resort, but it’s reassuring to know the option exists.

SVT in Babies and Young Children

SVT in newborns and infants is a different problem than in adults. In many cases, the abnormal electrical pathway that causes the arrhythmia resolves on its own during the first year of life, so the initial approach is usually antiarrhythmic medication rather than ablation. For most babies, that’s enough. However, some infants have SVT that doesn’t respond to drugs or that causes the heart muscle to weaken over time (a condition called tachycardia-induced cardiomyopathy). In those cases, catheter ablation becomes necessary even at a very young age.¹⁹ Improvements in mapping technology and accumulated experience have made ablation in very young children safer and more reliable than it was a decade ago.

One thing families should be aware of: a study looking at quality of life after ablation in children found clear improvements in physical, emotional, social, and school functioning compared to how kids were doing before the procedure. But the same study also found that roughly 30 percent of the children had at least one psychiatric diagnosis at follow-up, most commonly anxiety or depression.²⁰ Whether that anxiety came from the SVT itself, from the experience of medical procedures, or from something unrelated is hard to untangle. But it’s a signal that kids with SVT may benefit from emotional support alongside their cardiac care.

Why Wolff-Parkinson-White Demands Special Attention

Most forms of SVT are uncomfortable but not dangerous. Wolff-Parkinson-White (WPW) syndrome is the major exception. In WPW, an extra electrical pathway connects the upper and lower chambers of the heart. If that pathway conducts rapidly during atrial fibrillation (a different type of arrhythmia), it can allow dangerously fast signals to reach the ventricles and, in rare cases, trigger ventricular fibrillation, which is a cardiac arrest.²¹

This is why certain common medications that are safe for other types of SVT become hazardous in WPW. Digoxin, verapamil, and diltiazem can all increase conduction through the accessory pathway during atrial fibrillation, paradoxically making the situation worse. Ablation of the accessory pathway is strongly recommended for people with WPW, especially those who have had fast atrial fibrillation or who are in high-risk occupations. It’s one of the few scenarios where ablation is not just a quality-of-life decision but a safety one.

Smartwatches and SVT Detection

The proliferation of consumer wearables has created a new question for many people: can your smartwatch catch SVT? The short answer is that it can flag suspicious episodes, but the technology isn’t there yet for reliable diagnosis. A study evaluating smartwatch-based detection in the emergency department found that while the optical sensor (the green light on the back of the watch) caught SVT episodes with decent sensitivity, around 84 percent, its agreement with a proper 12-lead ECG diagnosis was poor. There was significant misclassification, and false-positive SVT alerts were more common in younger patients and women.²² A smartwatch recording may give your doctor a useful clue, especially if your episodes are infrequent and hard to catch on a traditional monitor, but it shouldn’t replace proper testing. If your watch keeps telling you your heart rate is 180 while you’re sitting still, that’s a prompt to see a cardiologist and get a proper workup, not a diagnosis.